Products
Platform
Research
Market
Learn
Compare Quant Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 2.4 | 1.87 |
NAV | ₹15.60 | ₹40.60 |
Fund Started | 27 Jun 2023 | 25 Jun 2018 |
Fund Size | ₹384.01 Cr | ₹6161.81 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹1000
₹100
Expense Ratio
2.4
1.87
NAV
₹15.60
₹40.60
Fund Started
27 Jun 2023
25 Jun 2018
Fund Size
₹384.01 Cr
₹6161.81 Cr
Exit Load
Exit load of 1%, if redeemed within 15 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -11.70% | 3.41% |
3 Year | - | 28.37% |
5 Year | - | 21.82% |
1 Year
-11.70%
3.41%
3 Year
-
28.37%
5 Year
-
21.82%
Holding Analysis
Equity | 98.58% | 95.88% |
Cash | -2.98% | 4.12% |
Equity
98.58%
95.88%
Cash
-2.98%
4.12%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Aster DM Healthcare Ltd. | 10.05% |
RPG Life Sciences Ltd. | 9.10% |
Anthem Biosciences Ltd. | 6.82% |
Zydus Wellness Ltd. | 6.75% |
Lupin Ltd. | 6.52% |
Sequent Scientific Ltd. | 6.51% |
Pfizer Ltd. | 6.44% |
Alivus Life Sciences Ltd | 6.06% |
HDFC Life Insurance Co Ltd. | 5.98% |
Aurobindo Pharma Ltd. | 5.82% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Dr. Reddy's Laboratories Ltd. | 9.47% |
Divi's Laboratories Ltd. | 9.23% |
Cipla Ltd. | 7.39% |
Aurobindo Pharma Ltd. | 6.53% |
Lupin Ltd. | 5.44% |
Alkem Laboratories Ltd. | 4.00% |
Mankind Pharma Ltd. | 3.50% |
Biocon Ltd. | 3.21% |
Gland Pharma Ltd. | 2.88% |
Fund Manager
Name | Ankit A Pande | Dharmesh Kakkad |
Start Date | 12 May 2023 | 16 Jan 2021 |
Name
Ankit A Pande
Dharmesh Kakkad
Start Date
12 May 2023
16 Jan 2021
About Fund
Description | The scheme seeks to long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 27 Jun 2023 | 25 Jun 2018 |
Description
The scheme seeks to long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
27 Jun 2023
25 Jun 2018
